<!DOCTYPE html>
<html lang="en">
<head id="Head1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="content-type" content="text/html;charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Full Text of HB3134</title>
    <link rel="shortcut icon" type="image/x-icon" href="https://cdn.ilga.gov/assets/img/site/favicon.ico" />
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap.min.css" />
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <script src="https://cdn.ilga.gov/assets/js/fontawesome/fa.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/jquery.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/js.cookie.min.js"></script>
    <script async src="https://cse.google.com/cse.js?cx=a47f92b5e11c1499a"></script> 
    <!-- Bootstrap Datepicker CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap-datepicker.min.css">
    <!-- Bootstrap Datepicker JavaScript -->
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap-datepicker.min.js"></script>
    <!-- aos, bootstrap icons, swiper CSS -->
    <link href="https://cdn.ilga.gov/assets/css/aos/aos.css" rel="stylesheet">
    <link href="https://cdn.ilga.gov/assets/css/swiper/swiper-bundle.min.css" rel="stylesheet">

    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.js"></script>

    <!-- ILGA main CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/main.css" />
    <link rel="stylesheet" type="text/css" media="print" href="https://cdn.ilga.gov/assets/css/print.css">
    <style></style>
    
</head>
<body>
        <!-- ======= Header ======= -->
        <header id="print-header" class="d-flex align-items-center">
            <div class="container-fluid align-items-center text-uppercase justify-content-start ">
                <div class="logo ">
                    <a href="/"><img src="https://cdn.ilga.gov/assets/img/site/white_capitol.png" alt="ILGA Logo"><span>ILGA.GOV</span></a>
                </div>
                <div class="w-100"></div>
            </div>
        </header>
    <input id="TextSearch" type="hidden" />
    <input id="MobileTextSearch" type="hidden" />
    <input id="message-input" type="hidden" />

    <main id="main-content" role="main">
        <section class="main-page p-2">
	<div class="p-1 pt-4 float-left">
		<div class="row border-bottom pb-3 mb-3">
			<div class="text-start">
				<h2>
					HB3134 - 104th General Assembly
				</h2><br />
			</div>
		</div>
		<div id="content">
			<!-- Full text only shows on large screens -->
			<div class="centered-container d-lg-flex">
				<div class="left-aligned-content">
					<div class="row">
						<div class="col pl-lg-5" translate="no">
							<text class="ml-5 text-left fulltextLineHeight" id="billtextanchor">
								<style>
								
								
								
								table.xsl	{ 	border-collapse: collapse;
												border: 0px solid black;
												font-family: "courier New"; 
												font-size: 10pt;}
								
								td.xsl		{ 	border-collapse: collapse;
												border: 0px solid black;
												padding-top: 3pt;
												padding-bottom: 3pt;
												padding-left: 0pt;
												padding-right: 0pt;
												font-family: "courier New"; 
												font-size: 10pt; }
												
								td.junk		{ 	width: 5%; }
								 
							
					
					
						body.xsl		{ 	text-align:center; }
						
					
						td.lineNum 		{ 	vertical-align: top; 
										  	text-align: right;
										  	font-family: "courier New"; 
										  	font-size: 10pt; }
							
						td.number 		{	width: 5%;
											vertical-align: top; 
										  	text-align: right;
										  	font-family: "Courier New", sans-serif;
										  	font-size: 10pt; }
						
						td.synopsis		{ 	border-collapse: collapse;
											border: 0px solid black;
											padding-top: 0pt;
											padding-bottom: 0pt;
											padding-left: 0pt;
											padding-right: 0pt;
											font-family: "courier New"; 
											font-size: 10pt; }
						
						td.rowsep		{ 	border-bottom: 1px solid black; }
											
						td.colsep		{ 	border-right: 1px solid black; }
											
						td.bothsep		{ 	border-right: 1px solid black;
										  	border-bottom: 1px solid black; }
	
						table.top		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black; }
											
						table.bottom	{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-bottom: 1px solid black; }
											
						table.sides		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black; }
	
						table.all		{ 	font-family: "Courier New", sans-serif;
										  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black;
									  	  	border-bottom: 1px solid black;
									  	  	border-top: 1px solid black; }				
	
						table.topbot	{ 	border-collapse: separate;
									  	  	border: outset 0pt;
										  	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black;
									  	  	border-bottom: 1px solid black; }
					
						.sigline		{ 	text-align: left;
							 		 		vertical-align: bottom;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.siglinetext		{ 	text-align: left;
							 		 		vertical-align: top;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.sigtitle		{ 	text-align: left;
							 				vertical-align: top;
							 				padding: 0pt; }
							 				  
						.sigtitlenum		{ 	text-align: right;
							 				vertical-align: top;
							 				padding: 0pt; }
							
						.siglinenum		{ 	text-align: right;
							 				vertical-align: center;
							 				padding-top: 3pt;
							 				padding: 0pt; }
					</style><table class="xsl" width="578"><pre><tr><td class="xsl" colspan="3"><p> </p><br> </td></tr></td></tr><tr><td class="number"></td><td class="junk"></td><td class="xsl"><table class="xsl" width="100%"><tr><td class="xsl"><center><b><pre><font size="3" face="Courier New">104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026</font><br>HB3134</pre></b></center><p> </p>Introduced 2/18/2025, by Rep. Hoan Huynh<p> </p><b>SYNOPSIS AS INTRODUCED:</b><br> </td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><table class="xsl" width="100%"><colgroup width="50%"></colgroup><colgroup width="50%"></colgroup><tr><td class="synopsis"><code>New Act</code></td><td class="synopsis"></td></tr></table><p></p></td></tr><tr><td class="xsl"><code>    </code><code>Creates the Canadian Prescription Drug Importation Act. Provides that </code><code>the Department of Public Health shall establish the Canadian prescription </code><code>drug importation program for the importation of safe and effective </code><code>prescription drugs from Canada which have the highest potential for cost </code><code>savings to the State. Provides that the Department shall contract with a </code><code>vendor to provide services under the program. Provides that by December 1, </code><code>2026 and each year thereafter, the vendor shall develop a wholesale </code><code>prescription drug importation list identifying the prescription drugs that </code><code>have the highest potential for cost savings to the State. Provides that the </code><code>vendor shall identify Canadian suppliers that are in full compliance with </code><code>the provisions of the Act and contract with the Canadian suppliers to </code><code>import drugs under the program. Provides for: a bond requirement; </code><code>requirements for eligible prescription drugs; requirements for eligible </code><code>Canadian suppliers; requirements for eligible importers; distribution </code><code>requirements; federal approval; prescription drug supply chain </code><code>documentation; immediate suspension of specified imported drug; </code><code>requirements of an annual report; notification of federal approval. </code><code>Provides that the Department shall adopt rules necessary to implement the </code><code>Act. Effective immediately.</code></td></tr><tr align="right" class="lineNum"><td class="xsl"><br><br></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left"></td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><p> </p><p> </p><center><b>A BILL FOR</b></center><p></p></td></tr></table><p> </p></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>AN ACT concerning health.</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><b><code>Be it enacted by the People of the State of Illinois, </code></b></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><b><code>represented in the General Assembly:</code></b><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 1. </code><code>Short title. </code><code>This Act may be cited as the </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>Canadian Prescription Drug Importation Act.</code><br> </td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 5. </code><code>Legislative findings. </code><code>The General Assembly </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>finds:</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(1) United States consumers pay some of the highest </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>prescription drug prices in the world, and it is estimated </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>that United States consumers pay twice as much as the amount </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>Canadian consumers pay for patented prescription drugs and 20% </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>more for generic drugs.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(2) Federal law, as codified in 21 U.S.C. 384, authorizes </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>the Secretary of the United States Department of Health and </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>Human Services to allow wholesale importation of prescription </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>drugs from Canada if such importation is shown to be both safe </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>and less costly for United States consumers.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(3) Although importing prescription drugs would be less </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>costly, there may be risks posed to consumer health and safety </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>if the source, quality, and purity of prescription drugs sold </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>by online pharmacies cannot be verified.</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(4) Canada has a rigorous regulatory system to license </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>prescription drugs, equivalent to the licensing system in the </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 2 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>United States.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(5) In the United States, Title II of the federal Drug </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>Quality and Security Act, referred to as the Drug Supply Chain </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>Security Act, has significantly improved drug security and </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>safety through a system of pharmaceutical product </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>track-and-trace procedures.</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(6) A wholesale drug importation program for the exclusive </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>benefit of residents of the State should be designed and </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>implemented to provide consumers of the State access to safe </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>and less expensive prescription drugs.</code><br> </td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 10. </code><code>Definitions. </code><code>As used in this Act:</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Canadian supplier means a manufacturer, wholesale </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>distributor, or pharmacy that is appropriately licensed or </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>permitted under Canadian federal and provincial laws and </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>regulations to manufacturer, distribute, or dispense </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>prescription drugs.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Department" means the Department of Public Health.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Drug" or prescription drug" has has the same meaning as </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>"drugs" in Section 1 of the Pharmacy Practice Act.</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Eligible importer" means an importer that is:</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) a pharmacist or wholesaler employed by or under </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>contract with a medicaid pharmacy, for dispensing to the </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>pharmacy's medicaid recipients;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) a pharmacist or wholesaler employed by or under </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>contract with the Department of Corrections, for </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 3 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>dispensing to inmates in the custody of the Department of </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>Corrections;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) a commercial plan, as defined by rules adopted by </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>the Department and as approved by the federal government; </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>and</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) a licensed pharmacist under the Pharmacy Practice </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>Act or registered wholesaler approved by the Department.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Federal act" means the federal Food, Drug, and Cosmetic </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>Act.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Medicaid pharmacy means a pharmacy licensed under the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>Pharmacy Practice Act that has a Medicaid provider agreement </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>in effect with the State and is in good standing with the </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>State.</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Pharmacist" means a person who holds and active and </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>unencumbered license to practice pharmacy under the Pharmacy </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>Practice Act.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Program" means the Canadian prescription drug importation </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>program created in this Act.</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Vendor" means a vendor with which the State who contracts </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>for the provision of services under the program pursuant to </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>subsection (a) of Section 15.</code><br> </td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 15. </code><code>Canadian prescription drug importation </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>program; importation process; contract with vendor; vendor </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>duties.</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) The Canadian prescription drug importation program is </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 4 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>created in the Department. Upon receiving approval of the </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>program as described in Section 25, the Department shall </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>contract with one or more vendors to provide services under </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>the program. For 3 years following the effective date of this </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>Act, the selection of any vendor pursuant to this subsection </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>is exempt from the requirements of the Illinois Procurement </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>Code.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Each vendor, in consultation with the Department and </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>any other vendors, shall establish a wholesale prescription </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>drug importation list that identifies the prescription drugs </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>that have the highest potential for cost savings to the State. </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>In developing the list, each vendor shall consider, at a </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>minimum, which prescription drugs will provide the greatest </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>cost savings to the State, including prescription drugs for </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>which there are shortages, specialty prescription drugs, and </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>high-volume prescription drugs. Each vendor shall revise the </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>list at least annually and at the direction of the State </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>department pursuant to this subsection. The Department shall </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>review the wholesale prescription drug importation list at </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>least every 3 months to ensure that it continues to meet the </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>requirements of the program. The Department may direct a </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>vendor to revise the list, as necessary. Each vendor, in </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>consultation with the Department, shall identify Canadian </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>suppliers who are in full compliance with relevant Canadian </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>federal and provincial laws and regulations and who have </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>agreed to export prescription drugs identified on the </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 5 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>wholesale prescription drug importation list. Each vendor </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>shall verify that such Canadian suppliers meet all of the </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>requirements of the program and will export prescription drugs </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>at prices that will provide cost savings to the State. Each </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>vendor shall contract with such eligible Canadian suppliers, </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>or facilitate contracts between eligible importers and </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>Canadian suppliers, to import prescription drugs under the </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>program. Each vendor shall assist the Department in developing </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>and administering a distribution program within the program. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>Each vendor shall assist the Department with the annual report </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>described in this Act and provide any information requested by </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>the Department for the report. Each vendor shall ensure the </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>safety and quality of drugs imported under the program, as </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>follows:</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) for an initial imported shipment, ensure that each </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>batch of the drug in the shipment is statistically sampled </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>and tested for authenticity and degradation in a manner </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>consistent with the federal act, and for any subsequent </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>imported shipment, ensure that a statistically valid </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>sample of the shipment is tested for authenticity and </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>degradation in a manner consistent with the federal act;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) certify that each drug: (i) is approved for </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>marketing in the United States and is not adulterated or </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>misbranded; and (ii) meets all of the labeling </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>requirements under 21 U.S.C. 352;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) maintain qualified laboratory records, including </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 6 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>complete data derived from all tests necessary to ensure </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>that the drug is in compliance with the requirements of </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>this Section; and</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) maintain documentation demonstrating that the </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>testing required by this Section was conducted at a </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>qualified laboratory in accordance with the Federal Act </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>and any other applicable federal and State laws and </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>regulations governing laboratory qualifications.</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) All testing required by this section must be conducted </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>in a qualified laboratory that meets the standards under the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>Federal Act and any other applicable federal and State laws </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>and regulations governing laboratory qualifications for drug </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>testing.</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) Each vendor shall maintain a list of all eligible </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>importers that participate in the program.</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Each vendor shall ensure compliance with Title II of </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>the federal Drug Quality and Security Act by all Canadian </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>suppliers, eligible importers, distributors, and other </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>participants in the program.</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) Each vendor shall provide an annual financial audit of </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>its operations to the Department. Each vendor shall also </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>provide quarterly financial reports specific to the program </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>and shall include information concerning the performance of </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>its subcontractors and vendors. The Department shall determine </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>the format and contents of the reports.</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) Each vendor shall submit evidence of a surety bond </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 7 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>with any bid or initial contract negotiation documents and </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>shall maintain documentation of evidence of such a bond with </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>the Department throughout the contract term. The surety bond </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>may be from this State or any other State in the United States </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>and must be in an amount of at least $25,000. The surety bond </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>or comparable security arrangement must include the State as a </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>beneficiary. In lieu of the surety bond, a vendor may provide a </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>comparable security agreement, such as an irrevocable letter </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>of credit or a deposit into a trust account or financial </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>institution that includes the State as a beneficiary, payable </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>to the State. The purposes of the bond or other security </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>arrangement are to:</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) ensure participation of the vendor in any civil or </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>criminal legal action by the State department, any other </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>State agency, or private individuals or entities against </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>the vendor because of the vendor's failure to perform </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>under the contract, including, but not limited to, causes </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>of actions for personal injury, negligence, and wrongful </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>death;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) ensure payment by the vendor through the use of a </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>bond or other comparable security arrangement of any legal </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>judgments and claims that are awarded to the State, other </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>entities acting on behalf of the State, individuals, or </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>organizations if the vendor is assessed a final judgment </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>or other monetary penalty in a court of law for a civil or </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>criminal action under the program. The bond or comparable </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 8 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>security arrangement may be accessed if the vendor fails </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>to pay any judgment or claim within 60 days after final </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>judgment; and</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) allow for civil and criminal litigation claims to </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>be made against the bond or other comparable security </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>arrangements for up to one year after the vendor's </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>contract under the program has ended with the Department, </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>the vendor's license is no longer valid, or the program </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>has ended, whichever occurs last.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(8) Each vendor shall maintain information and </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>documentation submitted under this Section for a period of at </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>least 7 years.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(9) The Department may require each vendor to collect any </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>other information necessary to ensure the protection of the </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>public health.</code><br> </td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 20. </code><code>Eligible prescription drugs; eligible Canadian </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>suppliers; eligible importers; distribution requirements.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) An eligible importer may import a prescription drug </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>from a Canadian supplier if:</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) the drug meets the United States Food and Drug </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>Administration's standards related to safety, </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>effectiveness, misbranding, and adulteration;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) importing the drug would not violate federal </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>patent laws; </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) importing the drug is expected to generate cost </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 9 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>savings; and </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) the drug is not: </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(i) a controlled substance as defined in 21 U.S.C. </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <code>802; </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(ii) a biological product as defined in 42 U.S.C. </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <code>262; </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(iii) an infused drug; </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(iv) an intravenously injected drug; </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(v) a drug that is inhaled during surgery; or </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(vi) a drug that is a parenteral drug, the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <code>importation of which is determined by the United </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <code>States Secretary of Health and Human Services to pose </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <code>a threat to the public health.</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) A Canadian supplier may export prescription drugs into </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>the State under the program if the supplier:</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) is in full compliance with relevant Canadian </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>federal and provincial laws and regulations; </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) is identified by the vendor as eligible to </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>participate in the program; and </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) submits an attestation that the supplier has a </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>registered agent in the United States, including the name </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>and United States address of the registered agent.</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) The following entities are eligible importers and may </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>obtain imported prescription drugs:</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) a pharmacist or wholesaler employed by or under </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>contract with a Medicaid pharmacy, for dispensing to the </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 10 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>pharmacy's Medicaid recipients; </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) a pharmacist or wholesaler employed by or under </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>contract with the Department of Corrections, for </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>dispensing to inmates in the custody of the Department of </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>Corrections; </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) commercial plans, as defined by rules promulgated </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>by the State Board and as approved by the federal </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>government; and </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) a licensed pharmacist or wholesaler approved by </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>the Department under the Pharmacy Practice Act.</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) The Department shall designate an office or division </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>that must be a licensed pharmaceutical wholesaler or that </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>shall contract with a licensed pharmaceutical wholesaler </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>licensed pursuant to Part 3 of Article 42.5 of Title 12. The </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>office or division designated by the Department shall:</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) set a maximum profit margin so that a wholesaler, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>distributor, pharmacy, or other licensed provider </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>participating in the program maintains a profit margin </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>that is no greater than the profit margin that the </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>wholesaler, distributor, pharmacy, or other licensed </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>provider whole have earned on the equivalent nonimported </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>drug;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) exclude generic products if the importation of the </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>products would violate United States patent laws </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>applicable to United States-branded products;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) comply with the requirements of 21 U.S.C. 360eee </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 11 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>through 360eee-4 as enacted in Title II of the federal </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>Drug Quality and Security Act; and</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) determine a method for covering the administrative </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>costs of the program, which method may include a fee </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>imposed on each prescription pharmaceutical product sold </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>through the program or any other appropriate method as </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>determined by the Department, but the Department shall not </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>require a fee in an amount the Department determines would </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>significantly reduce consumer savings.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Canadian suppliers and eligible importers </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>participating under the program:</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) shall comply with the tracking and tracing </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>requirements of 21 U.S.C. 360; and </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) shall not distribute, dispense, or sell </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>prescription drugs imported under the program outside of </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>the State.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) A participating eligible importer shall submit to the </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>vendor all of the following information about each drug to be </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>acquired by the importer under the program:</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) the name and quantity of the active ingredient of </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>the drug; </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) a description of the dosage form of the drug; </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) the date on which the drug is received; </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) the quantity of the drug that is received; </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) the point of origin and destination of the drug; </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>and</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 12 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) the price paid by the importer for the drug.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) A participating Canadian supplier shall submit to the </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>vender the following information about each drug to be </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>supplied by the Canadian supplier under the program:</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) the original source of the drug, including: </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(i) the name of the manufacturer of the drug; </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(ii) the date on which the drug was manufactured; </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <code>and </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(iii) the location including the country, state or </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >        <code>province, and city, where the drug was manufactured; </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) the date on which the drug is shipped; </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) the quantity of the drug that is shipped; </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) the quantity of each lot of the drug originally </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>received and the source of the lot; and</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) the lot or control number and the batch number </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>assigned to the drug by the manufacturer.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) The Department shall immediately suspend the </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>importation of a specific drug or the importation of drugs by a </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>specific eligible importer if it discovers that any drug or </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>activity is in violation of this Section or any federal or </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>State law or regulation. The Department may revoke the </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>suspension if, after conducting an investigation, it </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>determines that the public is adequately protected from </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>counterfeit or unsafe drugs being imported into this State.</code><br> </td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 25. </code><code>Federal approval. </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 13 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) On or before September 1, 2025, the Department shall </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>submit a request to the United States Secretary of Health and </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>Human Services for approval of the program under 21 U.S.C. </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>384. The Department shall begin operating the program within 6 </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>months after receiving such approval. The request must, at a </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>minimum: </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) describe the Department's plan for operating the </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>program; </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) demonstrate how the prescription drugs imported </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>into this State under the program will meet the applicable </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>federal and State standards for safety, effectiveness, </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>misbranding, and adulteration; </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) include a list of proposed prescription drugs that </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>have the highest potential for cost savings to the State </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>through importation at the time that the request is </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>submitted; </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) estimate the total cost savings attributable to </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>the program; </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) include a list of potential Canadian suppliers </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>from which the State would import drugs and demonstrate </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>that the suppliers are in full compliance with relevant </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>Canadian federal and provincial laws and regulations.</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Notwithstanding any provision of this subsection to </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>the contrary, the Department may expend money for the purpose </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>of requesting approval of the program as described in </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>subsection (a), but the Department shall not spend any other </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 14 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>money to implement the program until the Department receives </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>approval of the program as described in subsection (a).</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) Upon receipt of federal approval of the program, the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>Department shall notify the President of the Senate and the </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>Speaker of the House of Representatives, as well as the Health </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>and Human Services Committee of the Senate and the Health and </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>Insurance Committee of the House of Representatives, or any </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>successor committees. After approval is received and before </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>the start of the next regular session of the General Assembly </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>in which the proposal could be funded, the Department shall </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>submit to all parties specified in this subsection a proposal </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>for program implementation and program funding.</code><br> </td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 30. </code><code>Reports. </code><code>On or before December 1, 2026 and on </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>or before December 1 each year thereafter, the Department </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>shall submit a report to the Governor, the President of the </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>Senate, and the Speaker of the House of Representatives on the </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>operation of the program during the previous fiscal year. The </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>report must include, at a minimum: </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) a list of the prescription drugs that were </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>imported under the program; </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) the number of participating Canadian suppliers and </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>eligible importers; </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) the number of prescriptions dispensed through the </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>program; </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) the estimated cost savings during the previous </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 15 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>fiscal year and to date attributable to the program; </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) a description of the methodology used to determine </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>which drugs should be included on the wholesale </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>prescription drug importation list; and </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) documentation as to how the program ensures the </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>following that: </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(i) Canadian suppliers participating in the </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <code>program are in full compliance with relevant Canadian </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >        <code>federal and provincial laws; </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(ii) prescription drugs imported under the program </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <code>are not shipped, sold, or dispensed outside of this </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <code>State once in the possession of the eligible importer; </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(iii) prescription drugs imported under the </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <code>program are pure, unadulterated, potent, and safe; </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(iv) the program does not put consumers at a </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <code>higher health and safety risk than if the program did </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <code>not exist; and </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(v) the program provides cost savings to the State </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <code>on imported prescription drugs. </code><br> </td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 35. </code><code>Importation program authorized; rulemaking. </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) Upon approval by the Secretary, in accordance with </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>Section 30, the Department shall administer an importation </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>program.</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) The Department shall approve a method of financing and </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>administrative costs of the importation program, which method </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3134</td><td class="xsl" align="center">- 16 -</td><td class="xsl" align="right">LRB104 09684 BAB 19750 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>may include imposing a fee on each prescription pharmaceutical </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>product sold through the importation program or any other </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>appropriate method determined by the Department to finance </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>administrative costs. The Department shall not require a fee </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>in an amount that the Department determines would </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>significantly reduce consumer savings.</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) The Department shall adopt rules necessary to </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>implement this Act.</code><br> </td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 99. </code><code>Effective date. </code><code>This Act takes effect upon </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>becoming law.</code></pre></table>
							</text>
						</div>
					</div>
				</div>
			</div>
		</div>
    </div>
</section>
    </main>
    <!-- Vendor JS Files -->
    <script src="https://cdn.ilga.gov/assets/js/aos/aos.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/popper.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap.bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/glightbox/glightbox.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/swiper/swiper-bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/main.js"></script>

    

</body>
</html>
